Key result
Higher MR-proANP linked to ~50% higher post-stroke adverse event risk per doubling.
Why the study?
Patients remain at increased risk of adverse neurological and cardiovascular events after ischemic stroke or transient ischemic attack. This study evaluated whether cardiac biomarkers (NT-proBNP, MR-proANP, and hsTnI) and a two-step biomarker approach improve risk stratification.
Does a cardiac biomarker assessment (NT-proBNP, MR-proANP, and hsTnI) predict stroke severity and adverse events in patients after ischemic stroke or transient ischemic attack?
Cohort (n=273)
Does a cardiac biomarker assessment (NT-proBNP, MR-proANP, and hsTnI) predict stroke severity and adverse events in patients after ischemic stroke or transient ischemic attack?
MR-proANP concentrations independently predict stroke severity and post-stroke adverse events, and a two-step biomarker approach combining MR-proANP and hsTnI may improve risk stratification after ischemic stroke or transient ischemic attack.
Answers are grounded in this paper and cite their sources.
May inform post-stroke risk assessment; leaves open whether a two-step biomarker approach improves outcomes in prospective studies.
BACKGROUND AND PURPOSE: Following ischemic stroke or transient ischemic attack, patients remain at increased risk of adverse neurological and cardiovascular events. Cardiac biomarkers reflecting distinct pathomechanisms may improve risk stratification. We evaluated associations of N-terminal pro-B-type natriuretic peptide (NT-proBNP), midregional pro-atrial natriuretic peptide (MR-proANP), and high-sensitivity troponin I (hsTnI) with stroke severity and adverse events and explored a two-step biomarker approach to identify high-risk patients. Follow-up was available for 273 patients. Stroke severity was assessed by the National Institutes of Health Stroke Scale (NIHSS). Adverse events (death, myocardial infarction, recurrent stroke, rehospitalization) were recorded during a median of 278 days (interquartile range 184-367). Associations were investigated using age- and sex-adjusted linear, logistic, and Cox regression models. To explore whether combining biomarkers provides additional prognostic information, patients were stratified by the MR-proANP median, with those above the median further stratified by the subgroup-specific hsTnI median. RESULTS: Higher MR-proANP concentrations were associated with higher NIHSS scores on admission (adjusted β 0.64; 95% CI 0.25-1.02; p=0.001) and an increased risk of adverse events (adjusted HR 1.50; 95% CI 1.21-1.87; p<0.001). NT-proBNP showed similar but weaker associations, whereas hsTnI was not significantly associated with adverse events. Among patients with MR-proANP concentrations above the median, those with hsTnI concentrations above the subgroup-specific hsTnI median had the lowest event-free survival in Kaplan-Meier analysis (log-rank p=0.008). CONCLUSIONS: Cardiac biomarkers, particularly MR-proANP, provide prognostic information after ischemic stroke or transient ischemic attack. A two-step algorithm using MR-proANP for initial classification and hsTnI for refinement may identify patients at increased risk and requires prospective validation.
No takes yet. Share an insight, caveat, or question.
Gloystein et al. (2026) conducted a cohort in Ischemic stroke or transient ischemic attack (n=273). Cardiac biomarkers (MR-proANP, NT-proBNP, hsTnI) vs. Lower biomarker concentrations (evaluated per doubling and stratified by median) was evaluated on Composite of adverse events (death, myocardial infarction, recurrent stroke, rehospitalization) (HR 1.50, 95% CI 1.21-1.87, p=<0.001). Higher MR-proANP concentrations were associated with an increased risk of adverse events after stroke/TIA.
Synapse has enriched 10 related papers. Consider them for comparative context: